Introduction
============

Antisense oligonucleotides (ASO) bind to their cognate mRNA in cells and modulate RNA function.^[@bib1]^ However, unmodified oligonucleotides are highly unstable in biological media and require stabilization, either with chemical modifications or by formulation with cationic lipid based delivery vehicles, for use in animal experiments.^[@bib2]^ Second generation ASOs, which are amongst the most advanced oligonucleotides in the clinic, best illustrate the use of chemical modifications to improve the drug-like properties of ASOs.^[@bib3],[@bib4]^ The chemical design of a 2nd generation ASO includes a 8--14 base deoxynucleotide "gap," flanked on either end with 2--5 2′-*O*-methoxyethyl RNA (MOE) nucleotides. The gap region promotes degradation of the target mRNA by RNase H-mediated cleavage while the flanking MOE nucleotides enhance affinity for cognate RNA. To examine whether further increases in affinity could improve ASO potency, we replaced MOE nucleotides in the flanks of 2nd generation ASOs with locked nucleic acid (β-[D]{.smallcaps}-LNA 1, referred to as LNA henceforth; also known as 2′,4′-bridged nucleic acid or BNA, **[Figure 1](#fig1){ref-type="fig"}**).^[@bib5]^ This led to an increase in potency although this was sometimes accompanied by an increase in hepatotoxicity. Subsequent SAR studies showed that subtle structural changes to the LNA scaffold could change the therapeutic profile of ASOs containing these modifications. For example, introducing a methyl group in the (*R*) or (*S*) configuration at the 6′ (2′,4′-constrained-2′-*O*-ethyl BNA, *S*-cEt 2)^[@bib6],[@bib7]^ or the 5′-position (*S*-5′-Me-LNA 3 or *R*-5′-Me-LNA 4) of LNA^[@bib8]^ or replacing the 2′-oxygen atom in LNA with a substituted carbon atom,^[@bib9],[@bib10]^ improved the hepatotoxicity profile of the modified ASOs while maintaining activity relative to the parent LNA benchmark. To see if more drastic changes to the LNA scaffold could impact ASO therapeutic profile while maintaining activity, we replaced LNA nucleotides in the flanks with α-[L]{.smallcaps}-LNA 5 nucleotides.^[@bib11],[@bib12]^ α-[L]{.smallcaps}-LNA represents the α anomer of enantio-LNA ([L]{.smallcaps}-LNA) and also exhibits LNA-like high affinity recognition of complementary nucleic acids when incorporated into oligonucleotides.

Wengel and co-workers first identified α-[L]{.smallcaps}-LNA as a high affinity RNA recognition scaffold by screening all eight stereoisomers of LNA in thermal denaturation experiments.^[@bib11]^ Subsequent structural studies showed that α-[L]{.smallcaps}-LNA/DNA chimeric oligonucleotides form a seamless duplex with RNA and that the 2′,4′-bridge of α-[L]{.smallcaps}-LNA lies inside the major groove of the modified duplex.^[@bib13],[@bib14],[@bib15]^ Moreover, the duplexes exhibited an intermediate character between A- and B-type helical geometries. This discovery led to some initial excitement that such duplexes could serve as substrates for RNase H although this was found not to be the case later.^[@bib16]^ Fluiter compared the pharmacokinetic and antitumor properties of 16-mer LNA, 2′-thio-LNA, 2′-amino-LNA, and α-[L]{.smallcaps}-LNA modified phosphorothioate gapmer ASOs targeting H-Ras mRNA.^[@bib17]^ The study showed that all the modified ASOs had similar *T*~m~ and activity in cell culture for reducing H-ras mRNA. In addition, the α-[L]{.smallcaps}-LNA ASO showed activity similar to LNA for slowing tumor growth in a xenograft model. Despite the promising antitumor activity seen with the α-[L]{.smallcaps}-LNA ASO, no data regarding actual knockdown of H-ras mRNA in the animal experiment was provided to ascertain if the activity was indeed related to downregulation of H-ras gene in tumor tissue. The study also did not describe the effect of ASO treatment on genes expressed in the liver where the antisense effects of phosphorothoioate gapmer ASOs are best characterized. Moreover, while the above study was carried out with 16-mer ASOs, we and others have recently shown that it is possible to improve the potency of PS gapmer ASOs in animals by further reducing ASO length down to 14- or even 12-mers.^[@bib6],[@bib18],[@bib19]^

The interesting properties of α-[L]{.smallcaps}-LNA oligonucleotides spurred the synthesis of several structural analogs for use in oligonucleotide based diagnostic and therapeutic applications.^[@bib20],[@bib21],[@bib22],[@bib23],[@bib24]^ We recently reported the synthesis and biophysical properties of oligonucleotides modified with *R*-6′-Me-α-[L]{.smallcaps}-LNA 6,^[@bib25]^ *S*-5′-Me-α-[L]{.smallcaps}-LNA 7 and its *R*-5′-Me isomer 8,^[@bib26]^ and 3′-Me-α-[L]{.smallcaps}-LNA 9,^[@bib27]^ which also exhibit α-[L]{.smallcaps}-LNA like high affinity recognition of complementary nucleic acids but have increased steric bulk at different positions on the bicyclic scaffold (**[Figure 1](#fig1){ref-type="fig"}**). As seen in the LNA series, it was possible that introducing steric bulk at different locations of the α-[L]{.smallcaps}-LNA scaffold could modulate the biological properties of ASOs containing such modifications. In this report, we present the results from our detailed investigations of the SAR of 14-mer phosphorothioate gapmer ASOs modifed with α-[L]{.smallcaps}-LNA and related analogs. We show that these ASOs are capable of potent downregulation of gene expression in liver tissue without causing hepatotoxicity. However, in the sequence evaluated, α-[L]{.smallcaps}-LNA had a slightly higher propensity for causing increased immune stimulation which could be mitigated by replacing α-[L]{.smallcaps}-LNA monomers in the flanks of the ASO with *R*-5′-Me-α-[L]{.smallcaps}-LNA but not 6′-Me- or 3′-Me-α-[L]{.smallcaps}-LNA nucleotides.

Results
=======

To determine whether replacing LNA with α-[L]{.smallcaps}-LNA in the 3′- and 5′-flanks of PS modified gapmer ASOs has an effect on the hepatotoxicity profile, we first evaluated both modifications in a 14-mer (2-10-2 design) oligonucleotide targeting mouse phosphatase and tensin homologue (PTEN). This sequence shows elevations in plasma alanine aminotransferase (ALT) levels in mice even after a single injection of ASO A1 and was previously used by us to compare the hepatotoxicity profile of LNA and related analogs (**[Figure 2](#fig2){ref-type="fig"}**).^[@bib6],[@bib28]^ Mice (*n* = 4/group) were injected intraperitoneally with a single dose of 35 mg/kg of the LNA ASO A1 and α-[L]{.smallcaps}-LNA ASO A2 and PTEN mRNA in mouse liver and ALT levels were recorded post-sacrifice 72 hours after ASO administration. Both ASOs showed reductions in PTEN mRNA in liver tissue but LNA ASO A1 also showed an increase in ALT levels whereas the α-[L]{.smallcaps}-LNA ASO A2 did not.

To characterize the therapeutic profile of ASOs modified with LNA 1, *S*-cEt 2, *S*-5′-Me-LNA 3, α-[L]{.smallcaps}-LNA 5, *R*-6′-Me-α-[L]{.smallcaps}-LNA 6, *R*-5′-Me-α-[L]{.smallcaps}-LNA 8, and 3′-Me-α-[L]{.smallcaps}-LNA 9, we used a different 14-mer sequence also targeting mouse PTEN (**[Table 1](#tbl1){ref-type="table"}**). This sequence has been used by us extensively to profile the antisense properties of ASOs modified with tcDNA and a number of BNA and HNA analogs.^[@bib6],[@bib8],[@bib9],[@bib18],[@bib28],[@bib29]^ We first measured the *T*~m~ of ASOs A3--A9 versus complementary RNA and only observed minor differences in the ability of these modifications to stabilize oligonucleotide duplexes with complementary RNA. The LNA ASO A3 showed slightly higher *T*~m~ which can be attributed to using LNA T and 5-Me-C monomers, where each 5-Me group typically contributes +0.5 °C to overall *T*~m~.^[@bib30]^

Using the second sequence, we first evaluated LNA and α-[L]{.smallcaps}-LNA ASOs A3 and A4, respectively, in a single dose-escalation study (**[Figure 3](#fig3){ref-type="fig"}**). Mice (*n* = 4/group) were dosed intraperitoneally with a single dose of 3.2, 10, 32, and 100 mg/kg of LNA ASO A3 and α-[L]{.smallcaps}-LNA ASO A4 and PTEN mRNA reduction in mouse liver and plasma ALT levels were recorded post-sacrifice 72 hours after ASO administration. In this study, both ASOs showed almost identical knockdown of PTEN mRNA at both doses tested (**[Figure 3a](#fig3){ref-type="fig"}**). No ALT elevations were observed for the α-[L]{.smallcaps}-LNA ASO A4 at all evaluated doses while the LNA ASO A3 showed dramatic elevations in transaminase levels only for the high dose group treated animals (**[Figure 3b](#fig3){ref-type="fig"}**). No appreciable changes in liver and spleen weights were observed for either ASO in this experiment (**[Figure 3c--d](#fig3){ref-type="fig"}**).

We next compared LNA ASO A3, α-[L]{.smallcaps}-LNA ASO A4, *S*-cEt ASO A5, and *R*-6′-Me-α-[L]{.smallcaps}-LNA ASO A6 using a subchronic dosing schedule (**[Figure 4](#fig4){ref-type="fig"}**). This dosing schedule permits evaluation of the activity and immunostimulatory profile of ASOs in a clinically more relevant manner. Mice (*n* = 4/group) were injected intraperitoneally with 0.5, 1.5, 4.5, and 15 mg/kg twice a week for 3 weeks and PTEN mRNA knockdown in mouse liver and plasma ALT levels were recorded post-sacrifice 48 hours after last dose. All ASOs showed very similar potency for reducing PTEN mRNA in mouse liver, except for A6 which was twofold less potent despite very similar overall *T*~m~ (**[Figure 4a](#fig4){ref-type="fig"}**). In this dosing regimen, all ASOs evaluated achieved near maximal PTEN mRNA knockdown at the 15 mg/kg dose but the LNA ASO A3-treated mice showed elevated ALT levels while ASOs A4, A5, and A6 did not (**[Figure 4b](#fig4){ref-type="fig"}**). This is consistent with previous observations where LNA gapmers produced ALT increases at doses which resulted in maximal target mRNA knockdown.^[@bib5]^ All the ASOs except A5, showed a moderate dose-dependent increase in liver weights (**[Figure 4c](#fig4){ref-type="fig"}**). Interestingly, the α-[L]{.smallcaps}-LNA ASO A4 and to a greater degree, the *R*-6′-Me-α-[L]{.smallcaps}-LNA ASO A6 showed drug induced dose-dependent increases in spleen weight (**[Figure 4d](#fig4){ref-type="fig"}**) indicative of increased immune stimulation.^[@bib31]^ In contrast, the LNA and *S*-cEt ASOs A3 and A5, respectively, did not show a similar dose-dependent increase in spleen weights.

To examine whether other α-[L]{.smallcaps}-LNA analogs also produced similar increases in spleen weights, we evaluated the 3′-Me- and *R*-5′-Me-α-[L]{.smallcaps}-LNA modified ASOs A7 and A8, respectively in mice (**[Figure 5](#fig5){ref-type="fig"}**). The *S*-5′-Me-LNA ASO A9 was included as the control. We had previously evaluated *S*-5′-Me-LNA ASO A9 in animal experiments and found it to be approximately twofold less potent than LNA ASO A3.^[@bib8]^ However, the 5′-Me group was very effective in suppressing even the modest ASO induced spleen weight increase produced by the LNA ASO A3 in that study. Mice (*n* = 4/group) were dosed with ASOs A7, A8, and A9 at 2.5, 7.9, and 25 mg/kg twice a week for 3 weeks and liver mRNA downregulation and plasma ALT levels were recorded post-sacrifice 48 hours after last ASO administration. In this study, the *S*-5′-Me-LNA ASO A9 showed the best activity for PTEN mRNA reduction in mouse liver followed by the *R*-5′-Me-α-[L]{.smallcaps}-LNA ASO A8 whereas the 3′-Me-α-LNA ASO A7 was the least active (**[Figure 5a](#fig5){ref-type="fig"}**) but the differences in activity were minor. The 3′-Me- and *R*-5′-Me-α-[L]{.smallcaps}-LNA ASOs A7 and A8, respectively, showed modest dose-dependent increases in liver weights but none of these ASOs produced elevations in ALT levels at all the doses evaluated (**[Figure 5b](#fig5){ref-type="fig"}**). However, the 3′-Me-α-[L]{.smallcaps}-LNA ASO A7 showed more than twofold increase in spleen weight for the 7.9 and 25 mg/kg ASO-treated groups. In contrast, the *R*-5′-Me-α-[L]{.smallcaps}-LNA ASO A8 and the *S*-5′-Me-LNA ASO A9 showed minimal increases in spleen weight changes (**[Figure 5d](#fig5){ref-type="fig"}**).

Discussion
==========

To help understand the relative orientations of the different methyl groups in the LNA versus the α-[L]{.smallcaps}-LNA series and to examine whether these differences could help explain the observed biological effects, we created structural models by overlaying dimeric units of each modification from the published NMR structures of the modified duplexes (**[Figure 6](#fig6){ref-type="fig"}**).^[@bib15],[@bib32]^ We used the duplex structures to extrapolate the relative orientations of the methyl groups on the LNA and α-[L]{.smallcaps}-LNA scaffolds and their structural relationship with the PS backbone in single stranded ASOs. Previous studies have utilized crystal structures of dinucleoside phosphates with natural and modified sugars, as starting points to generate the double helical structures of oligonucleotide duplexes.^[@bib33],[@bib34]^ Thus, it is reasonable to expect that the modified dinucleotide units with rigid and locked furanose rings in the flanks of ASOs A3--A9 have similar overall conformations in the single strands as those observed in the duplexes.

By overlaying the common elements such as the nucleobases, the 1′-carbon and the 4′-oxygen atoms, it becomes readily apparent that the α-[L]{.smallcaps}-LNA sugar-phosphate backbone is distinctly different from the LNA sugar-phosphate backbone (**[Figure 6a](#fig6){ref-type="fig"}**). In addition, while the 2′,4′-bridge resides in the minor groove for LNA modified duplexes, this bridge lies in the major groove for α-[L]{.smallcaps}-LNA modified duplexes. As a consequence, introducing substitution on the 2′,4′-bridge of LNA directs the substituent toward the minor groove while analogous substitution in the α-[L]{.smallcaps}-series directs the substituent into the major groove of the modified duplex. An illustration of this concept can be gained by comparing the relative orientation of the 6′-methyl groups in *S*-cEt 2 (*S*-6′-Me-LNA) versus *R*-6′-Me-α-[L]{.smallcaps}-LNA 6 (**[Figure 6c--d](#fig6){ref-type="fig"}**). In both cases, the methyl group (light green) points toward the 3′-hydroxyl group in the nucleoside monomer. However this group lies at the edge of the minor groove in the LNA series^[@bib35]^ while it lies at the edge of the major groove in the α-[L]{.smallcaps}-series. In contrast, introducing a methyl group at the 3′-position (pink) of α-[L]{.smallcaps}-LNA projects this group into the minor groove of the modified duplex. The analogous substitution in LNA was not explored as substituting at this position disrupts hybridization by interfering with base stacking in the major groove.^[@bib36]^

The relative orientation of the methyl groups at the 5′-position in LNA and α-[L]{.smallcaps}-LNA are more difficult to estimate. Assuming canonical orientations around torsions angles α, β, and γ, the *S*-configured 5′-Me group (dark blue) in LNA is most likely situated in the minor groove and occupies a position distinctly different from that of the 6′-Me group (*S*-cEt). We had previously shown that the *R*-5′-Me-LNA (olive green) analog 4 had a destabilizing effect on duplex stability relative to LNA and the *S*-5′-Me analog 3.^[@bib8]^ Structural insights into this destabilizing effect were obtained by examining the crystal structures of *R*- and *S*-6′-Me substituted fluoro hexitol nucleic acid modified DNA duplexes which, like BNA modified duplexes, also exist in the A-type conformation.^[@bib37]^ In that case, the *R*-6′-Me group caused an energetically unfavored 1...5 steric clash with the 3′-phosphodiester linkage resulting in duplex instability. This destabilizing interaction is intrinsic to all A-form duplexes where the sugar moieties exists in the C3′-endo sugar pucker. Interestingly, while the energetically disfavored 1...5 interaction also exists in the α-[L]{.smallcaps}-LNA scaffold (**[Figure 6b](#fig6){ref-type="fig"}**) the *R*-5′-Me-α-[L]{.smallcaps}-LNA analog 8 had a greater stabilizing effect on duplex thermal stability as compared the *S*-5′-Me isomer 7.^[@bib26]^ Previous NMR studies on the *R*-5′-Me-α-[L]{.smallcaps}-LNA nucleoside monomer had indicated conformational mobility around torsion angle γ suggesting that the sugar-phosphate backbone in α-[L]{.smallcaps}-LNA nucleotides might be capable of adopting alternate low energy conformations in addition to the one observed in the NMR structure of the modified duplex with RNA.^[@bib26]^

Based on the above analysis there appear to be no obvious structural reasons for the differential effects on spleen weights produced by the α-[L]{.smallcaps}-LNA ASO. It is also unclear if the methyl groups in different locations on the LNA and α-[L]{.smallcaps}-LNA scaffold are changing the binding properties of these ASOs to any putative immune receptors. However, it is known that several nucleic acid sensing proteins recognize chemically modified nucleic acids such as PS DNA, with or without functional consequences, by binding to the sugar-phosphate backbone in a sequence independent manner.^[@bib38]^ Thus an alternate explanation for the observed effects could be that the 6′- and the 3′-methyl groups in α-[L]{.smallcaps}-LNA stabilize certain nucleic acid backbone conformation/s that is/are intrinsically more proinflammatory. In contrast, introducing a methyl group at the 5′-position in close proximity to the phosphorothioate linkage, shields the ASO sugar-phosphate backbone from being recognized efficiently by the immune receptors. Alternatively, the 5′-methyl group produces subtle changes in the backbone conformation such that the ASO is not recognized as efficiently by the immune receptors. Either one of these events could be responsible for the mitigation in ASO proinflammatory profile observed in our studies.

In conclusion, we report for the first time, the antisense properties of RNase H active PS gapmer ASOs modified with α-[L]{.smallcaps}-LNA and related analogs in animals. We find that α-[L]{.smallcaps}-LNA ASOs are capable of potent downregulation of gene expression in liver tissue without producing hepatoxicity. However, the α-[L]{.smallcaps}-LNA ASO showed a slightly increased propensity for causing immune stimulation in the oligonucleotide sequence used for evaluation in the present study. The ALT elevations seen with the LNA/DNA gapmer ASOs seen in this work and previous studies^[@bib5],[@bib6],[@bib8],[@bib9],[@bib29]^ is in contrast to recent reports using non-gapmer LNA/DNA mixmer ASOs targeting miR122^[@bib39],[@bib40]^ highlighting that sequence and design can significantly alter ASO therapeutic profile.

Similarly, while we only evaluated α-[L]{.smallcaps}-LNA in the context of two sequences, extensive profiling of this modification in several different sequences and motifs is required to arrive at general conclusions regarding any perceived benefits of this scaffold for lowering the risk of hepatotoxicity. Our results also suggest that introducing steric bulk at the 5′-position, in close proximity to the PS linkage, could be a general strategy for reducing the immunostimulatory profile of ASOs. In a clinical setting, proinflammatory effects manifest themselves as injection site reactions and flu-like symptoms. Thus, a mitigation of these effects could increase patient comfort and compliance when treated with ASOs.

Materials and Methods
=====================

*Oligonucleotide synthesis and purification*. LNA phosphoramidites were purchased from commercially available sources while other phosphoramidites were synthesized according to procedures described previously.^[@bib7],[@bib8],[@bib12]^ Oligonucleotides A1--A9 were synthesized at 40 µmol scale using UnyLinker PS200 universal support, 0.2 mol/l phenylacetyldisulfide in 1:1 3-picoline:acetonitrile as a sulfur-transfer reagent and 0.7 mol/l dicyanoimidazole in acetonitrile as the activator. All phosphoramidites were used at 0.1 mol/l concentration in acetonitrile. For each of the modified analogs 4-fold excess of amidite was delivered with a 12-minute coupling time. The 5′-end dimethoxytrityl group was left on to facilitate purification. After synthesis was complete, all oligonucleotides were treated with 1:1 triethylamine:acetonitrile to remove the cyanoethyl protecting group from the phosphorothioate linkages. Subsequently, oligonucleotides were treated with concentrated aqueous NH~4~OH at 55 °C for 9--12 hours to cleave from support, remove heterocyclic protecting groups, and hydrolyze the UnyLinker moiety. Oligonucleotides were purified by ion-exchange chromatography using a gradient of NaBr across Source 30Q resin, with the 5′-DMT group being removed during purification using 6% (vol/vol) aqueous dichloroacetic acid. Pure fractions were desalted by binding to a C18 reverse-phase column and eluting with 50% (vol/vol) acetonitrile in water.

*T~m~ measurements*. For the *T*~m~ experiments, oligonucleotides were prepared at a concentration of 8 µmol/l in a buffer of 100 mmol/l NaCl, 10 mmol/l phosphate, 0.1 mmol/l EDTA at pH 7. The concentration of oligonucleotides was determined at 85 °C. The final oligonucleotide concentration was 4 µmol/l with mixing of equal volumes of test oligonucleotide and complementary RNA strand. Oligonucleotides were hybridized with the complementary RNA strand by heating duplex to 90 *°*C for 5 minutes and allowed to cool to room temperature. Using the spectrophotometer, *T*~m~ measurements were taken by heating duplex solution at a rate of 0.5 °C/minute in cuvette starting at 15 °C and heating to 85 °C. *T*~m~ values were determined using van\'t Hoff calculations (A~260~ versus temperature curve) using non-self-complementary sequences where the minimum absorbance which relates to the duplex and the maximum absorbance which relates to the non-duplex single strand are manually integrated into the program. Sequence of the RNA complement used for ASOs A1 and A2 was 5′-r(GGAAGCTGCAGCCATGATGG)-3′ and for ASOs A3--A9 was 5′-r(TCAAGGCCAGTGCTAAGAGT)-3′.
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*Protocols for animal experiments and RNA analysis*. The Institutional Animal Care and Use Committee (IACUC) approved all procedures. Male Balb/c mice were housed 4/cage on a 12:12-hour light/dark cycle. ASO solutions were prepared in PBS and injected intraperitoneally twice a week at various concentrations for 3 weeks. Mice were sacrificed 48 hours after the last dose. Blood samples were collected by cardiac puncture, diluted 1:3 with physiological saline and plasma chemistries values were measured on the Olympus AU400 Clinical Analyzer (Beckman Coulter, CA). For the RNA analysis, liver tissues were homogenized in 4 mol/l guanidine isothiocyanate, 25 mmol/l EDTA, 50 mmol/l Tris--HCl pH 6 containing 1 mol/l β-mercaptoethanol immediately following sacrifice and homogenized. RNA was extracted using RNeasy columns (Qiagen, Valencia, CA) according to manufacturer\'s protocol. RNA was eluted from the columns with water. RNA samples were analyzed by fluorescence-based quantitative reverse transcription (RT)-PCR using an Applied Biosystems 7700 sequence detector (Applied Biosystems, Carlsbad, CA). Levels of target RNAs as well as those of cyclophilin A, a housekeeping gene, were determined. Target RNA levels were normalized to cyclophilin levels for each RNA sample. Primers used for determination of PTEN RNA level are as follows: FP 5′-ATGACAATCATGTTGCAGCAATTC-3′, RP 5′-CGATGCAATAAATATGCACAAATCA-3′, and PR 5′-6FAM- CTGTAAAGCTGGAAAGGGACGGACTGGT-TAMRA-3′. Primers used for determination of cyclophilin A RNA level are as follows: FP 5′-TCGCCGCTTGCTGCA-3′′, RP 5′-ATCGGCC GTGATGTCGA-3′, and PR 5′-6FAM-CCATGGTCAACCCCACC GTGTTC-TAMRA-3′.

![**Structures and duplex stabilizing properties of LNA, *S*-cEt, *R*-5′-Me-LNA, *S*-5′-Me-LNA, α-[L]{.smallcaps}-LNA, *R*-6′-Me-α-[L]{.smallcaps}-LNA, *R*-5′-Me-α-[L]{.smallcaps}-LNA, *S*-5′-Me-α-[L]{.smallcaps}-LNA, and 3′-Me-α-[L]{.smallcaps}-LNA in oligonucleotide sequences used for biophysical studies**. LNA, locked nucleic acid.](mtna201234f1){#fig1}

![**Evaluation of LNA and α-[L]{.smallcaps}-LNA antisense oligonucleotides (ASOs) for hepatotoxicity in mice**. Mice (n = 4/dose group) were injected intraperitoneally (i.p.) with a single dose of 35 mg/kg of ASOs A1 and A2 formulated in saline and animals were sacrificed 72 hours after injection. (a) Phosphatase and tensin homologue (PTEN) mRNA reduction in liver normalized to saline-treated animals and plasma alanine aminotransferase (ALT) levels post-sacrifice. (b) Sequence and T~m~ of ASOs A1 and A2 versus complementary RNA. Modified nucleotides are indicated in bold font, all errors in ±SD. LNA, locked nucleic acid.](mtna201234f2){#fig2}

![**Evaluation of LNA and α-[L]{.smallcaps}-LNA antisense oligonucleotides (ASOs) A3 and A4 for activity and hepatotoxicity in a single-dose--escalation study in mice**. Mice (*n* = 4/dose group) were injected intraperitoneally (i.p.) with a single dose of 3.2, 10, 32, and 100 mg/kg of ASOs A3 and A4 formulated in *saline* and animals were sacrificed 72 hours after injection. (**a**) Phosphatase and tensin homologue (PTEN) mRNA reduction in liver normalized to saline-treated animals (**b**) plasma alanine aminotransferase (ALT) levels post-sacrifice. Percent change in (**c**) liver and (**d**) spleen weights relative to saline-treated animals. LNA, locked nucleic acid.](mtna201234f3){#fig3}

![**Evaluation of LNA A3, α-[L]{.smallcaps}-LNA A4, *S*-cEt A5, and *R*-6′-Me-α-[L]{.smallcaps}-LNA A6 for activity and hepatotoxicity in a 3-week dose-escalation study.** Mice (*n* = 4/dose group) were injected intraperitoneally (i.p.) twice a week for 3 weeks with of 0.5, 1.5, 4.5, and 15 mg/kg of antisense oligonucleotides (ASOs) formulated in saline and animals were sacrificed 48 hours after last injection. ASOs A3, A4, and A5 were evaluated in one study while ASO A6 was evaluated in a parallel study using LNA ASO A3 as a control. Data for the LNA ASO (*n* = 8) reflects the average measurements from both studies while data for ASOs A4, A5, and A6 (*n* = 4) is from the individual studies (**a**) phosphatase and tensin homologue (PTEN) mRNA reduction in liver normalized to saline-treated animals (**b**) plasma alanine aminotransferase (ALT) levels post-sacrifice. Percent change in (**c**) liver and (**d**) spleen weights relative to saline-treated animals. All errors in ±SD.](mtna201234f4){#fig4}

![**Evaluation of 3′-Me-α-[L]{.smallcaps}-LNA A7, *R*-5′-Me-α-[L]{.smallcaps}-LNA A8, and *S*-5′-Me-LNA A9 for activity and hepatotoxicity in a 3-week dose-escalation study.** Mice (*n* = 4/dose group) were injected intraperitoneally (i.p.) twice a week for 3 weeks with 2.5, 7.9, and 25 mg/kg of antisense oligonucleotides (ASOs) formulated in saline and animals were sacrificed 48 hours after last injection. (**a**) Phosphatase and tensin homologue (PTEN) mRNA reduction in liver normalized to saline-treated animals (**b**) plasma alanine aminotransferase (ALT) levels post-sacrifice. Percent change in (**c**) liver and (**d**) spleen weights relative to saline-treated animals. All errors in ±SD. LNA, locked nucleic acid.](mtna201234f5){#fig5}

![**Structural models of LNA and α-[L]{.smallcaps}-LNA dinucleotide units showing relative orientations of 3′-Me, 5′-Me, and 6′-Me groups**. (**a**) Overlay of common structural units such as nucleobases, C1′ carbon and O4′ oxygen atoms of LNA (pink carbons) and α-[L]{.smallcaps}-LNA (teal carbons) dimers obtained from the NMR structures of modified DNA/RNA duplexes (refs. [@bib32] and [@bib15]). Complementary RNA strand not shown for clarity. (**b**) Structures of the monomeric units showing relative orientations of various methyl groups. (**c**) Relative orientations of *S*-6′-Me (light green), R-5′-Me (olive green), and S-5′-Me (dark blue) groups in a LNA dinucleotide unit. (**d**) Relative orientations of *R*-6′-Me (light green), R-5′-Me (olive green), S-5′-Me (dark blue), and 3′-Me (pink) groups in an α-[L]{.smallcaps}-LNA dinucleotide unit. LNA, locked nucleic acid.](mtna201234f6){#fig6}

###### Sequence, *T*~m~ and ED~50~ (mg/kg) values for LNA, α-[L]{.smallcaps}-LNA, *S*-cEt, *R*-6′-Me-α-[L]{.smallcaps}-LNA, 3′-Me-α-[L]{.smallcaps}-LNA, *R*-6′-Me-α-[L]{.smallcaps}-LNA, *S*-5′-Me-LNA ASOs A3--A9, respectively, targeting mouse PTEN
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